Unknown PHASE4 INTERVENTIONAL 2-arm NCT00941642

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

Sponsor: GlaxoSmithKline

Conditions Non-Alcoholic Fatty Liver Disease

Updated 6 times since 2017 Last updated: Jun 9, 2010 Started: Sep 30, 2009 Primary completion: Sep 30, 2012 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00941642, this PHASE4 trial focuses on Non-Alcoholic Fatty Liver Disease and remains ongoing. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Huntington Medical Research Institutes

Data source: Huntington Medical Research Institutes

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pasadena, United States